- Q4 2023 Vaxcyte Inc Earnings Call TranscriptFeb 27, 2024€75.5 (+7.09%)Earnings
- Vaxcyte Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Vaxcyte Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Vaxcyte Inc VAX-24 Phase 2 65+ Adult Study Results Call TranscriptApr 17, 2023
- Q4 2022 Vaxcyte Inc Earnings Call TranscriptFeb 27, 2023€39.2 (-2.49%)Earnings
- Vaxcyte Inc VAX-24 Phase 1/2 Proof-of-Concept Study Topline Data Call TranscriptOct 24, 2022
- Vaxcyte Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Vaxcyte Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Q4 2021 Vaxcyte Inc Earnings Call TranscriptFeb 28, 2022€19.9 (+0.51%)Earnings
- Vaxcyte Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) TranscriptOct 05, 2021
- Vaxcyte Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q4 2020 Vaxcyte Inc Earnings Call TranscriptMar 29, 2021Earnings
Vaxcyte Inc VAX-24 Phase 1/2 Proof-of-Concept Study Topline Data Call Transcript
Good morning. My name is Olivia, and I'll be your conference operator today. At this time, I would like to welcome everyone to Vaxcyte's VAX-24 Phase I/II Proof-of-Concept Study Results of Conference Call. (Operator Instructions) I would now like to turn the call over to Andrew Guggenheim, President and Chief Financial Officer of Vaxcyte.
Great. Thanks, everyone, and thanks, operator, and good morning, everyone. I'd like to welcome you to Vaxcyte's conference call to discuss top line results from our Phase I/II Proof-of-Concept Study, evaluating the safety, tolerability and immunogenicity of VAX-24, the company's investigational 24-valent pneumococcal conjugate vaccine in healthy adults aged 18 to 64.
I'm joined this morning by our Chief Executive Officer, Grant Pickering; and our Chief Operating Officer, Jim Wassil. Early this morning, we issued a news release announcing our top line results and the presentation, we will be reviewing today, will be made available shortly on our website and via
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)